| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC3548 |
| Trial ID | NCT05989828 |
| Disease | Triple-Receptor Negative Breast Cancer |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NY-ESO-1 TCR-T cells |
| Co-treatment | Biopsy |
| HLA | HLA-A2 |
| Phase | Phase1 |
| Recruitment status | Not Recruiting |
| Title | Phase Ib Clinical Trial of Autologous Anti-NY-ESO-1 TCR-Engineered T Cells in Patients With Relapsed/Refractory Locally Advanced or Metastatic NY-ESO-1-Expressing Triple Negative Breast Cancer |
| Year | 2023 |
| Country | United States |
| Company sponsor | University of Southern California |
| Other ID(s) | 1B-23-1|NCI-2023-04697|1B-23-1|P30CA014089|2018-002987-14 |
| Cohort 1 | |||||||||
|
|||||||||